You are here

Which drug causes the least number of side effects in the treatment of metastatic prostate cancer in men and is it effective?

In this systematic review, researchers sought to compare different remedies for preventing skeletal complications in men with prostate cancer. 

Author: Aigerim Akhmetova 

Translator: Akhmetova Aigerim 

 

 

Prostate(prostate gland)-it's a gland in the male reproductive system. Prostate cancer can spread to other parts of the body, including bones. Bone metastases in men with prostate cancer can lead to skeletal complications such as fractures or intolerable pain. 

 

Extensive searches were conducted in various databases until March 23, 2020, comparing various bone-modifying agents with each other or without further treatment or placebo treatment (dummy treatment) men with prostate cancer and bone metastases. 

 

Two drugs were mainly compared: zoledronic acid and denosumab. Treatment with zoledronic acid and denosumab probably does not reduce or increase mortality compared to no treatment/placebo(low evidence). 

 

The results show that it is zoledronic acid that increases both the proportion of participants with a pain response and the proportion of participants experiencing side effects, but in order to draw a complete picture and confirm the results of this analysis, more research is needed with a direct comparison of all potential agents. 

 

Source: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013020.pub2/full 

Top